指南与共识脊柱关节炎

ASAS关于中轴型脊柱关节炎临床试验报告的建议

ASAS recommendations on reporting axial spondyloarthritis clinical trials.
指南 / 共识 · Ann Rheum Dis · 2025-09-06

该研究基于ASAS核心结局指标集更新版,由指导组和工作组制定中轴型脊柱关节炎临床试验基线特征与结局报告建议,经2024年ASAS年度研讨会成员投票通过。最终定义了42项通用基线特征和8项疾病修饰药物试验附加特征,并提出20项试验结局及11项非核心指标集工具结局的报告建议,成员赞成率分别为84%、85%和93%。

要点

  • ASAS制定中轴型脊柱关节炎临床试验报告建议,涵盖基线特征与结局。
  • 定义42项通用基线特征及8项疾病修饰药物试验附加特征。
  • 提出20项试验结局及11项非核心指标集工具结局的报告建议。

核心结论

  • 这些获ASAS认可的中轴型脊柱关节炎临床试验报告建议,为报告基线特征和结局提供了标准化方法。

研究设计与样本

  • 指导组召集了由13名ASAS成员组成的工作组,成员包括风湿病学家、方法学家、流行病学家和2名ASAS青年成员。
  • 建议制定分三步:指导组从关键中轴型脊柱关节炎临床试验中识别相关基线特征并提出结局呈现方案;工作组会议讨论修改;2024年ASAS年度研讨会成员讨论并投票。

主要发现

  • 定义了42项适用于所有中轴型脊柱关节炎临床试验的基线特征,以及8项疾病修饰药物试验附加特征,并包括报告方式描述。
  • 提出了在基线和随访时间点报告20项试验结局的建议。
  • 制定了报告11项ASAS认可但不在核心结局指标集中的工具结局的建议。
  • 基线特征、核心结局指标集结局和非核心结局指标集结局的提案分别获84%、85%和93%的ASAS成员赞成。

关键数值与推荐

  • 42项基线特征适用于所有中轴型脊柱关节炎临床试验,8项附加特征适用于疾病修饰药物试验。
  • 20项试验结局需在基线和随访时间点报告。
  • 11项工具结局为ASAS认可但不在核心结局指标集中,需按建议报告。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aims to develop recommendations on reporting baseline features and outcomes from axial spondyloarthritis (axSpA) clinical trials based on the recently updated instrument set of the Assessment of SpondyloArthritis international Society (ASAS) core outcome set (COS). METHODS: A steering group (SG) convened a workgroup (WG), consisting of 13 ASAS members including rheumatologists, methodologists, epidemiologists, and 2 Young ASAS members. Recommendations on reporting axSpA trials baseline features and outcomes were developed in 3 steps: (1) the SG identified relevant baseline features from key axSpA clinical trials and formulated a proposal on how outcomes related to the instruments in the ASAS COS should be presented. (2) The SG proposal was presented, discussed, and modified in WG meetings. (3) WG proposal was discussed and voted on by ASAS members during the 2024 annual ASAS workshop. RESULTS: Forty-two baseline features relevant for all axSpA clinical trials and 8 additional features for disease-modifying drug trials were defined including descriptions on how to report them. Additionally, recommendations on how to report 20 trial outcomes at baseline and follow-up timepoints were put forward. Finally, recommendations on how to report 11 outcomes of instruments additionally endorsed by ASAS but not in the COS were formulated. Proposals for baseline features, COS outcomes, and outcomes not in COS were approved by ASAS members (with 84%, 85%, and 93% of members in favour, respectively). CONCLUSIONS: These ASAS-endorsed recommendations on axSpA clinical trial reporting provide a standardised approach to reporting both baseline features as well as outcomes from axSpA clinical trials.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. van Gaalen FA, Navarro-Compán V, Baraliakos X, et al. ASAS recommendations on reporting axial spondyloarthritis clinical trials. Ann Rheum Dis. 2025. PMID: 40915940. doi:10.1016/j.ard.2025.07.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。